Mezagitamab
- Generic Name
- Mezagitamab
- Drug Type
- Biotech
- CAS Number
- 2227490-52-8
- Unique Ingredient Identifier
- 0XMR8L9LOL
- Background
Mezagitamab is under investigation in clinical trial NCT04278924 (Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/chronic Primary Immune Thrombocytopenia).
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 347
- Registration Number
- NCT06963827
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06948318
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 171
- Registration Number
- NCT06722235
- Locations
- 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hebei, China
🇨🇳The First Affiliated Hospital of Nanchang University - Donghu Campus, Nanchang, Jiangxi, China
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
- Conditions
- Kidney DiseaseGlomerulonephritis
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 16
- Registration Number
- NCT05174221
- Locations
- 🇸🇬
National University Hospital- Singapore, Singapore, Singapore
🇦🇺Core Research Group, Milton, Queensland, Australia
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT04776018
- Locations
- 🇺🇸
Mayo Clinic Arizona - PPDS, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 41
- Registration Number
- NCT04278924
- Locations
- 🇧🇬
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia, Sofia-Grad, Bulgaria
🇸🇮Univerzitetni klinicni Center Ljubljana, Ljubljana, Slovenia
🇧🇬University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria
A Study of TAK-079 in People With Generalized Myasthenia Gravis
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT04159805
- Locations
- 🇺🇸
Neurology and Sleep Disorders Clinic, Columbia, Missouri, United States
🇮🇹Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇺🇸The University of Arizona Medical Center, Tucson, Arizona, United States
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT03984097
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus ErythematosusLupus Erythematosus, Systemic
- Interventions
- Drug: TAK-079 Placebo
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03724916
- Locations
- 🇺🇸
ACRC Studies, Poway, California, United States
🇺🇸North Georgia Rheumatology Group-Duluth, Lawrenceville, Georgia, United States
🇺🇸Southwest Rheumatology Research, LLC, Mesquite, Texas, United States
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Conditions
- Relapsed/RefractoryMultiple Myeloma
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03439280
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸Weill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.